{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T17:57:34Z","timestamp":1788717454110,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.cllc.2023.08.011","type":"journal-article","created":{"date-parts":[[2023,8,13]],"date-time":"2023-08-13T17:39:36Z","timestamp":1691948376000},"page":"641-650.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Improved Survival Outcomes in Patients With MET-Dysregulated Advanced NSCLC Treated With MET Inhibitors: Results of a Multinational Retrospective Chart Review"],"prefix":"10.1016","volume":"24","author":[{"given":"J\u00fcrgen","family":"Wolf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Jean","family":"Souquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Cortot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Baik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Heist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Youn","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel W.","family":"Neal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron S.","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Gilloteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngozi","family":"Nwana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maeve","family":"Waldron-Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith L.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Giovannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark M.","family":"Awad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.cllc.2023.08.011_bib0001","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1158\/1078-0432.CCR-16-0229","article-title":"MET Exon 14 alterations in lung cancer: exon skipping extends half-life","volume":"22","author":"Drilon","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.cllc.2023.08.011_bib0002","doi-asserted-by":"crossref","first-page":"e99399","DOI":"10.1371\/journal.pone.0099399","article-title":"Prognostic value of MET gene copy number and protein expression in patients with surgically resected non-small cell lung cancer: a meta-analysis of published literatures","volume":"9","author":"Guo","year":"2014","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.cllc.2023.08.011_bib0003","first-page":"389","article-title":"Targeting MET in NSCLC: looking for a needle in a haystack","volume":"3","author":"Landi","year":"2014","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"10.1016\/j.cllc.2023.08.011_bib0004","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jtho.2016.10.019","article-title":"Targeting MET exon 14 skipping alterations: has lung cancer MET its match?","volume":"12","author":"Yap","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2023.08.011_bib0005","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13045-019-0759-9","article-title":"MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer","volume":"12","author":"Wang","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.cllc.2023.08.011_bib0006","series-title":"United States & Canadian Academy of Pathology (USCAP)","article-title":"SC32-predictive biomarkers: lessons from clinical trials","volume":"Abstract #SC32","author":"Buettner","year":"2017"},{"issue":"9","key":"10.1016\/j.cllc.2023.08.011_bib0007","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107677","article-title":"MET gene copy number predicts worse overall survival in patients with non-small cell lung cancer (NSCLC): a systematic review and meta-analysis","volume":"9","author":"Dimou","year":"2014","journal-title":"PLoS One"},{"issue":"suppl 15","key":"10.1016\/j.cllc.2023.08.011_bib0008","doi-asserted-by":"crossref","first-page":"8511","DOI":"10.1200\/JCO.2017.35.15_suppl.8511","article-title":"Impact of MET inhibitors on survival among patients (pts) with MET exon 14 mutant (METdel14) non-small cell lung cancer (NSCLC)","volume":"35","author":"Awad","year":"2017","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"10.1016\/j.cllc.2023.08.011_bib0009","doi-asserted-by":"crossref","first-page":"8512","DOI":"10.1200\/JCO.2017.35.15_suppl.8512","article-title":"PD-L1 expression and response to immunotherapy in patients with MET exon 14-altered non-small cell lung cancers (NSCLC)","volume":"35","author":"Sabari","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.cllc.2023.08.011_bib0010","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer","volume":"383","author":"Wolf","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.cllc.2023.08.011_bib0011","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2023.08.011_bib0012","unstructured":"Novartis Pharmaceutical Corporation. TABRECTA (capmatinib) [package insert]. U.S. Food and Drug Administration website. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213591s000lbl.pdf. Accessed January 29, 2021."},{"key":"10.1016\/j.cllc.2023.08.011_bib0013","unstructured":"FDA grants accelerated approval to tepotinib for metastatic non-small cell lung cancer. Available at https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-grants-accelerated-approval-tepotinib-metastatic-non-small-cell-lung-cancer. Accessed March 05, 2021."},{"key":"10.1016\/j.cllc.2023.08.011_bib0014","doi-asserted-by":"crossref","first-page":"S1057","DOI":"10.1016\/j.annonc.2022.07.1231","article-title":"1106P capmatinib for METex14 non-small cell lung cancer patients: results of the real-world study IFCT-2104 CapmATU","volume":"33","author":"Ferreira","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2023.08.011_bib0015","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221103206","article-title":"Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program","volume":"14","author":"Illini","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.cllc.2023.08.011_bib0016","article-title":"Characterization of non-small-cell lung cancers with MET exon 14 skipping alterations detected in tissue or liquid: clinicogenomics and real-world treatment patterns","volume":"5","author":"Lee","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"12","key":"10.1016\/j.cllc.2023.08.011_bib0017","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1158\/1078-0432.CCR-15-2061","article-title":"MET amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis","volume":"22","author":"Tong","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.cllc.2023.08.011_bib0018","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jtho.2020.11.017","article-title":"Genetic heterogeneity of MET-aberrant NSCLC and its impact on the outcome of immunotherapy","volume":"16","author":"Kron","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"7","key":"10.1016\/j.cllc.2023.08.011_bib0019","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1200\/JCO.2015.63.4600","article-title":"MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression","volume":"34","author":"Awad","year":"2016","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.cllc.2023.08.011_bib0020","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jtho.2016.06.004","article-title":"characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations","volume":"11","author":"Schrock","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1016\/j.cllc.2023.08.011_bib0021","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jtho.2016.11.2221","article-title":"Increasing rates of no treatment in advanced-stage non-small cell lung cancer patients: a propensity-matched analysis","volume":"12","author":"David","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"8","key":"10.1016\/j.cllc.2023.08.011_bib0022","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1158\/2159-8290.CD-15-0285","article-title":"Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors","volume":"5","author":"Frampton","year":"2015","journal-title":"Cancer Discov"},{"issue":"19","key":"10.1016\/j.cllc.2023.08.011_bib0023","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.cllc.2023.08.011_bib0024","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jtho.2019.12.129","article-title":"Efficacy and safety of anti-PD-1 immunotherapy in patients with advanced NSCLC with BRAF, HER2, or MET mutations or RET translocation: GFPC 01-2018","volume":"15","author":"Guisier","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"8","key":"10.1016\/j.cllc.2023.08.011_bib0025","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry","volume":"30","author":"Mazieres","year":"2019","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.cllc.2023.08.011_bib0026","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1093\/annonc\/mdy334","article-title":"PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers","volume":"29","author":"Sabari","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2023.08.011_bib0027","unstructured":"National Comprehensive Cancer Network: Non-small cell lung cancer (version 2.2021). Available at https:\/\/www.nccn.org\/professionals\/physician_gls\/default.aspx#nscl. Accessed June 07, 2022."},{"issue":"suppl 15","key":"10.1016\/j.cllc.2023.08.011_bib0028","doi-asserted-by":"crossref","first-page":"9020","DOI":"10.1200\/JCO.2021.39.15_suppl.9020","article-title":"Capmatinib in MET exon 14-mutated, advanced NSCLC: updated results from the GEOMETRY mono-1 study","volume":"39","author":"Wolf","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730423001729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730423001729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:15:18Z","timestamp":1761506118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730423001729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S1525730423001729"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2023.08.011","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improved Survival Outcomes in Patients With MET-Dysregulated Advanced NSCLC Treated With MET Inhibitors: Results of a Multinational Retrospective Chart Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2023.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}